Business Wire

2022 Blue Planet Prize: Announcement of Prize Winners - THE ASAHI GLASS FOUNDATION

15.6.2022 05:00:00 EEST | Business Wire | Press release

Share

This year marks the 31st awarding of the Blue Planet Prize, the international environmental award sponsored by the Asahi Glass Foundation, chaired by Takuya Shimamura. Every year, the Foundation selects two winners, individuals or organizations who have made significant contributions to the resolution of global environmental problems. The Board of Directors have selected the following 2022 Blue Planet Prize recipients.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220608006214/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

2022 recipients: (1) His Majesty Jigme Singye Wangchuck, the Fourth King of Bhutan; (2) Professor Stephen Carpenter (USA) (Graphic: Business Wire)

2022 recipients

His Majesty Jigme Singye Wangchuck, the Fourth King of Bhutan
Born in the Kingdom of Bhutan, Date of Birth: 11 November, 1955
His Majesty Jigme Singye Wangchuck, the Fourth King of Bhutan, is the visionary leader who introduced the development philosophy of Gross National Happiness (GNH) which places the well being of the people at the heart of development activities and programmes. GNH gives importance to environmental conservation, sustainable and equitable development, and promotion of culture and social values which contribute to collective happiness. Using happiness as a social indicator was taken on by the United Nations and OECD also employed it in their reports, giving inspiration for an alternative paradigm to modern society.

Professor Stephen Carpenter (USA)
Born in the USA, Date of Birth: 5 July, 1952
Emeritus Director of the Center for Limnology,
Stephen Alfred Forbes Professor Emeritus of Integrative Biology, University of Wisconsin-Madison
Professor Stephen Carpenter has conducted research on lake ecosystems for more than 40 years. Through his research on lake eutrophication, from nutrients such as phosphorus and nitrogen, he studied the resilience of lakes using mathematical models, providing a new perspective on social-ecological systems. He also worked on the environmental pollution from phosphorus and nitrogen through land use, showing the critical state of the global phosphorus cycle and the need to review human activity from a broad geochemical viewpoint.

Each recipient is presented with a certificate of merit, a commemorative trophy, and 50 million Japanese yen in prize money.
We would like to hold the Blue Planet Prize Award Ceremony and commemorative lectures, which could well be on a smaller scale, while taking proper measures to prevent infection with the new coronavirus. The Award Ceremony is scheduled on Wednesday, October 5, 2022 at Tokyo Kaikan. Commemorative lectures will be given on October 6 and 8, 2022, at the University of Tokyo and at Kyoto University, respectively.
This press release and the photo of each recipient will be published 11 a.m. on Wednesday June 15 on the website of the Asahi Glass Foundation (www.af-info.or.jp/en).

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

THE ASAHI GLASS FOUNDATION
Toshihiro Tanuma, PhD
TEL: +81 3 5275 0620
FAX: +81 3 5275 0871
E-mail: post@af-info.or.jp

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye